At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRXT Clarus Therapeutics Holdings, Inc.
Not Yet Opened 12-19 16:00:00 EST Delay
Testosterone Drug Maker Clarus Files For Bankruptcy -- Market Talk
BRIEF-Clarus Therapeutics Expects To Recognize Up To About $1.1 Mln In Total For Severance, Related Expenses For Employees Laid Off Under Reduction In Force
Clarus Therapeutics Filed Non-timely 10-Q With SEC; Said Due to Result of Workforce Reduction That Being Implemented, Co Requires Additional Time to Complete Preparation of Form 10-Q
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.